CENTESSA PHARMACEUTICALS PLC financials

CNTA CIK 0001847903

Source: EDGAR filings · Built 2026-06-19T02:10:38Z

Custom taxonomy namespace: ffd

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Free Cash Flow -194.19M -142.09M -160.51M -201.68M -135.29M -10.63M
EBITDA -206.77M -200.11M -170.47M -212.13M -374.05M -10.44M
Working Capital 324.94M 478.41M 275.71M 399.41M 604.14M 2.55M
Net Debt 57.08M -265.39M -42.94M -323.84M -519.38M -1.60M
Operating Margin -1384.61% -2499.39%
Net Margin -1316.88% -2204.65%
Return on Equity (ROE) -37.49% -58.71% -63.95% -64.31% -77.52%
Return on Assets (ROA) -28.73% -40.87% -41.94% -48.66% -60.52% -91.00%
Current Ratio 8.57× 9.25× 8.00× 11.42× 25.52× 1.30×
Debt-to-Equity 0.22× 0.29× 0.36× 0.21× 0.15×
Effective Tax Rate -0.93% -1.22% 14.22% 0.34% -0.03% 0.00%
Cash Conversion Ratio 0.98× 0.60× 1.06× 0.93× 0.35× 1.00×
Accruals Ratio -0.01× -0.16× 0.03× -0.04× -0.39× -0.00×
SBC % of Revenue 206.41% 428.89%
CapEx Coverage -522.42× -4178.09× -948.77× -176.38× -726.39×
Free Cash Flow Per Share $-1.43 $-1.24 $-1.67 $-2.16 $-1.80

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Revenues 15.00M 0 6.85M 0
Operating Income (Loss) -207.69M -201.06M -171.28M -212.26M -374.08M -10.44M
Income Tax Expense (Benefit) 1.82M 2.84M -25.06M -747.00K 114.00K 0
Net Income (Loss) Attributable to Parent -197.53M -235.76M -151.09M -216.21M -381.07M -10.66M
Earnings Per Share, Basic $-1.46 $-2.06 $-1.57 $-2.31 $-5.07
Weighted Average Number of Shares Outstanding, Basic 135.72M 114.47M 96.18M 93.40M 75.17M
Earnings Per Share, Diluted $-1.46 $-2.06 $-1.57 $-2.31 $-5.07
Weighted Average Number of Shares Outstanding, Diluted 135.72M 114.47M 96.18M 93.40M 75.17M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Cash and Cash Equivalents, at Carrying Value 61.30M 383.22M 128.03M 393.64M 595.08M 7.23M
Assets, Current 367.88M 536.41M 315.09M 437.75M 628.77M 11.16M
Assets 687.50M 576.80M 360.25M 444.31M 629.63M 11.72M
Long-term Debt 110.09M 108.94M 0
Liabilities, Current 42.94M 58.00M 39.38M 38.34M 24.64M 8.62M
Long-term Debt, Excluding Current Maturities 110.09M 108.94M 75.70M 69.80M 75.70M 0
Liabilities 160.63M 175.25M 124.00M 108.14M 138.08M 8.62M
Stockholders' Equity Attributable to Parent 526.86M 401.55M 236.24M 336.17M 491.55M
Common Stock, Shares, Outstanding 149.23M 132.63M 98.77M 94.84M 89.99M 0

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Net Cash Provided by (Used in) Operating Activities -193.82M -142.06M -160.34M -200.55M -135.11M -10.63M
Payments to Acquire Property, Plant, and Equipment 371.00K 34.00K 169.00K 1.14M 186.00K 0
Net Cash Provided by (Used in) Investing Activities -418.53M 31.27M -127.00M -931.00K 63.26M 0
Payments for Repurchase of Common Stock 12.00K 0
Net Cash Provided by (Used in) Financing Activities 291.53M 364.75M 21.12M 457.00K 660.15M 1.36M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (CNTA CIK 0001847903), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

RCAT

Red Cat Holdings, Inc.

ARWR

ARROWHEAD PHARMACEUTICALS, INC.

HAVA

Harvard Ave Acquisition Corporation